

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

VOLUNTARY ANNOUNCEMENT

PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) AS FIRST-LINE TREATMENT FOR HER2+ ADVANCED BREAST CANCER MET PRIMARY ENDPOINT

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Group about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that a phase III clinical study of Anbenitamab (trade name: 恩尼妥®, R&D code: KN026), co-developed with Shanghai JMT-Bio Technology Co., Ltd. (上海津曼特生物科技有限公司) (“**JMT-Bio**”), a subsidiary of CSPC Pharmaceutical Group Limited (“**CSPC Group**”) (Stock Code: 1093), in combination with the docetaxel (albumin-bound) for injection (HB1801) as first-line treatment for human epidermal growth factor receptor 2 (“**HER2**”)-positive (“**HER2+**”) advanced breast cancer (study code: KN026-003), based on the assessment by the Independent Data Monitoring Committee (the “**IDMC**”), successfully met the pre-specified primary endpoint of progression-free survival (“**PFS**”), with results demonstrating both statistically significant and clinically meaningful benefits.

Breast cancer ranks among the top high-incidence malignant tumors among women in China, with the HER2+ subtype accounting for approximately 20% to 30% of cases. In China, approximately 20% of patients with breast cancer are already at an advanced stage upon initial diagnosis, and approximately 10% of patients with HER2+ early breast cancer experience disease recurrence within three years after radical surgery. Trastuzumab in combination with pertuzumab and docetaxel (the “**THP regimen**”) remains the preferred first-line treatment for HER2+ advanced breast cancer in China and globally. Although the THP regimen has significantly prolonged PFS in such patients, approximately 50% of patients still experience disease progression within two years, indicating substantial unmet clinical needs.

KN026-003 is a randomized, controlled, open-label, multi-center phase III clinical study designed to enroll approximately 880 patients with HER2+ advanced breast cancer, who are randomized at a 1:1 ratio. The study aims to compare the efficacy and safety of KN026 in combination with HB1801 against the THP regimen as first-line treatment for HER2+ advanced breast cancer, with PFS as assessed by the Blinded Independent Review Committee as the primary endpoint. As assessed by the IDMC, KN026 in combination with HB1801 significantly prolonged PFS and reduced the risk of disease progression or death as compared with the THP regimen, and also showed a trend of overall survival benefit. Detailed data from the study will be presented at an upcoming international academic conference.

ABOUT 恩尼妥® (ANBENITAMAB INJECTION)

恩尼妥® (Anbenitamab injection, R&D code: KN026) is an anti-HER2 bispecific antibody independently developed by the Company using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). Anbenitamab can simultaneously bind two non-overlapping epitopes of HER2, resulting in HER2 signal blockade. Through antibody-induced receptor clustering, it enhances antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effects while promoting the down-regulation of HER2 receptors on the cell surface.

In May 2026, 恩尼妥® obtained approval for marketing from the National Medical Products Administration of China (國家藥品監督管理局) (the “NMPA”) through the priority review and approval pathway for combination with chemotherapy as the treatment of adult patients with locally advanced or metastatic HER2+ gastric cancer/gastroesophageal junction cancer who have previously received at least one trastuzumab-containing regimen. The phase III clinical study of neoadjuvant treatment for HER2+ breast cancer has reached its primary endpoint, and a New Drug Application (NDA) will be submitted in the near future. Currently, multiple registrational clinical studies of Anbenitamab for indications such as first-line treatment of HER2+ breast cancer, adjuvant treatment of HER2+ breast cancer and first-line treatment of HER2+ gastric cancer/gastroesophageal junction cancer are ongoing.

Anbenitamab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of HER2+ or HER2-low gastric cancer. It has also been granted Breakthrough Therapy Designation by the NMPA as second-line or above treatment of HER2+ gastric cancer/gastroesophageal junction cancer.

In August 2021, we entered into a licensing agreement with JMT-Bio, pursuant to which JMT-Bio was granted exclusive development and commercialization rights for Anbenitamab in breast cancer and gastric cancer indications within Mainland China (excluding Hong Kong, Macau, and Taiwan).

ABOUT DOCETAXEL (ALBUMIN-BOUND) FOR INJECTION (HB1801)

Docetaxel (Albumin-Bound) for Injection (HB1801) is one of the flagship drugs independently developed by CSPC Group on its proprietary nanomedicine technology platform. With docetaxel encapsulated in human serum albumin and free of Tween-80 and ethanol, HB1801 has the following advantages over conventional docetaxel injection: (1) Safety: No steroid premedication is needed. It can be rapidly administered at high concentrations, featuring superior safety and better patient compliance; (2) Efficacy: It has exhibited remarkable efficacy in multiple preclinical tumor models and several clinical studies. Higher doses can be applied clinically to further improve therapeutic outcomes.

HB1801 has currently entered pivotal phase III registrational clinical trials for indications including breast cancer and gastric cancer.

ABOUT THE COMPANY

The Company is a leading biopharmaceutical company in the PRC with a fully integrated proprietary technology platform in antibody-drug conjugates (“ADC(s)”), bispecific antibodies and multi-functional protein engineering. The Company’s highly differentiated in-house pipeline consists of ADCs, monoclonal antibodies and bispecific antibodies in staggered development status in oncology, including, among others, two products approved for marketing by the NMPA and multiple products in phase III or pivotal clinical trial stages. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that KN026 will be successfully developed and/or marketed for indications other than the use in combination with chemotherapy for the treatment of adult patients with locally advanced or metastatic HER2+ gastric cancer/gastroesophageal junction cancer who have previously received at least one trastuzumab-containing treatment regimen. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, June 10, 2026

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.